StockWatch
·
LIFE INSURANCE CORPORATION OF INDIA · QQ2 FY-2027 · THE CALL

VNB margin recovery offsets weak APE growth; regulatory headwinds loom

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsLICILife Insurance Corporation of India13 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

VNB margin guidance (mid-20s) achieved at 22.3%; APE acceleration guidance missed—grew 3.2%, not accelerating. PAT +20% met.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

LIC posted solid VNB and margin expansion—hitting mid-20s guidance—but APE growth remains tepid (3.21%) despite promised ULIP recovery. Market share eroded slightly to 58.77%; regulatory uncertainty on distribution commission caps poses execution risk. Strong operational momentum is offset by macro-dependent growth headwinds.

₹13436.1 Cr

Revenue · +16.1% YoY

₹12114.8 Cr

Reported PAT · +20% YoY

Expanding

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

APE growth to accelerate in Q2+ as ULIP recovers

MISS

H1 APE growth 3.21% (30,696 cr vs 29,744 cr); ULIP still declining 40%+; not accelerating

VNB margin expected to improve toward mid-20s

MET

VNB margin at 22.3% (up 470 bps YoY from 17.6%); target achieved

Protection business showing strong growth

MET

Protection APE growth 58.59% YoY; confirmed strong momentum

Market share stable in individual and group

OVERSTATED

Market share down to 58.77% from 59.41% YoY; slight erosion

PAT growth 21.52% on H1 basis

MET

Delivered PAT YoY growth 20.0%; H1 claim aligns with annual metric

Earnings quality

What changed since the last call

Deltas vs. the prior call

VNB margin +470 bps YoY

Upgrade

Margin at 22.3% (Sep 2026) vs 17.6% (Sep 2025). Driven by product mix shift to non-PAR, higher-margin pure protection, and operational efficiency gains. Aligns with mid-20s guidance.

APE growth stalled

Downgrade

H1 APE up 3.21% (₹30,696 cr) vs 3.2% claimed acceleration in prior call. ULIP down 40%+, slowing individual APE. Group APE +14% but cannot offset ULIP drag. Missed implicit acceleration guidance.

Market share erosion

Downgrade

Market share by FYPIP dropped to 58.77% from 59.41% YoY (64 bps loss). Competition or slower growth in individual segment. Group market share stable at 70.45%.

Non-PAR mix compression

Downgrade

Non-PAR APE share fell to 34.02% from 36.31%; PAR now 65.98%. Non-PAR savings up 35% but still losing portfolio share. Long-term margin support weakens if non-PAR shrinks.

Protection business inflection

Upgrade

Pure protection APE up 58.59% (₹157 cr). New launches (Health Shield, Cancer Cover) driving traction. Small base but high-margin trajectory supports future profitability.

The Q&A

Analysts pressed hard on margin walk (non-PAR mix vs term business), ULIP recovery timing, and commission cap impact on agents. Management held firm on margin defense (product mix, expense ratio focus) and regulatory stance but deferred specifics to actuarial team. Tone was assured but somewhat repetitive.

The exchanges that mattered

Distribution regulation, commission impact — Avinash Singh, Emkay Global

Partial

Distribution reform caps commission rate; LIC uniquely positioned via agent productivity focus, training, product mix shift. Will maintain competitive positioning despite commission cut.

VNB margin components and assumptions — Nischint Chawthe, Kotak Securities

Answered

Non-PAR savings +350 bps (8% contribution), term growth +3%, RFR down 40 bps offset by business mix. Margin improvements from product interventions and operational efficiency, expected to improve further.

APE growth, product mix, non-PAR decline — Swarnabha Mukherjee, 360 ONE Capital

Partial

Product mix shift: high-ticket annuity, non-PAR savings, term business, protection growing. APE de-growth from ULIP temporary; market recovery expected, agents trained. Protection to drive long-term growth.

Annuity product growth, pricing — Mohit Mangal, Centrum

Answered

No IRR changes; annuity spread among many agents; single-premium focus to offset low-ticket monthly. Strategy to increase agent productivity and client base via annuity training.

Group business slowdown, ULIP mix drag — Mohit Mangal, Centrum

Dodged

Group APE +14%; market share down due to cyclical rate movements and competition. Interest rate cycles affect group pricing. Market share broadly stable; no near-term concern.

Bancassurance channel growth and partnership — Shobhit Sharma, Elara Securities

Partial

Bancassurance now favorable to LIC; added Yes Bank, RBL. IDBI stake sale reduces dependency (was 50%, now 30%). Expanding partnerships; traction expected as market improves.

ULIP outlook, market recovery timing — Prayesh Jain, Motilal Oswal

Answered

ULIP market-dependent; 30% of agents trained to sell ULIPs; recovery expected as market bounces. Growth muted current year but confident in rebound. Agents already positioned.

Office rationalization, expense ratio targets — Prayesh Jain, Motilal Oswal

Partial

Ongoing work; digital adoption and process re-engineering underway. Expect expense ratio improvements in coming quarters via higher centralization and automation.

Hedge and interest rate exposure on non-PAR book — Sanketh Godha, Avendus Spark

Answered

Hedge ~80% of premium; hardening rates help; maturity hedge ladder in place. Managed well under interest-rate environment; low near-term risk.

RBC capital, solvency outlook, dividend sustainability — Dipanjan Ghosh, Goldman Sachs

Partial

Solvency ratio strong; pending RBC rules will guide capital actions. Focused on profitability and managing capital conservatively. Position ample for growth and potential dividend.

Guidance

Forward guidance and management's confidence

No explicit FY27 revenue or APE numeric guidance

Low

Management discussed mid-20s VNB margin target and APE recovery pending ULIP market recovery; no FY27 revenue CAGR stated

VNB margin targeting mid-20s (achieved 22.3% H1)

High

Margin expansion driven by product mix (non-PAR, pure protection), operational efficiency (expense ratio controls), and yield tailwinds. Expected to improve further H2.

Risks the call surfaced

Ranked by how much they should concern a holder

Regulatory — Distribution commission reform

High

IRDA consultation on agent commission caps; LIC relies heavily on agent channel (91.81% of new business). Commission cuts could reduce agent productivity, incentive alignment, and new policy sales.

Market — ULIP segment de-growth

High

ULIP APE down >40% H1; market-driven weakness persists. APE growth promise (3%+) depends on ULIP recovery. If equity volatility continues, agents de-motivate, and growth targets missed.

Competitive — Market share erosion

Medium

Market share in individual FYPIP declined 64 bps YoY to 58.77%. Private players gaining in high-margin segments (annuity, pure protection). If trend continues, margin pressure or growth slowdown.

Financial — Non-PAR mix compression

Medium

Non-PAR APE share fell to 34.02% from 36.31%. While individual non-PAR savings APE +35% YoY, portfolio share declining. Long-term VNB margin support weakens if non-PAR base shrinks relative to PAR.

Regulatory — RBC capital framework uncertainty

Medium

RBC solvency guidelines pending finalization. Solvency ratio 2.35x is ample now, but final guidelines could tighten capital requirements. May force capital raise or constrain dividends/growth if rules unfavorable.

Management

Score 7/10. Clear on margin walk and product strategy; deferred detail on actuarial assumptions to Srivastava; withheld specifics on regulatory feedback. Transparent on market conditions, less so on internal targets. Track record mixed: VNB margin guidance (mid-20s) achieved at 22.3%; APE acceleration guidance missed (3.21% growth, not accelerating). PAT +20% met. Digital initiatives (MyLIC 4.7 rating, ANANDA +41%) executing well.

What to watch next
  • 1 · H2 FY27

    IRDA distribution regulation final guidance; impact on agent economics and channel growth unclear

  • 2 · H2 FY27

    New product ramp (Dhara-II, health shield, cancer cover); target 100k+ policies to offset ULIP weakness

  • 3 · Sep 2026+

    RBC solvency capital rules; may require capital raise or restrict growth if guidelines tighten

Strong operational momentum is offset by macro-dependent growth headwinds.

Informational and educational content only. Not investment advice.